Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1359 ARTÍCULOS , VIENDO DEL 1201 AL 1215

APP transgenic mice: their use and limitations

Balducci C, Forloni G.

Neuromolecular Med. 2011 Jun;13(2):117-37. doi: 10.1007/s12017-010-8141-7. Epub 2010 Dec 9.

Citicoline in vascular cognitive impairment and vascular dementia after stroke

Alvarez-Sabín J, Román GC.

Stroke. 2011 Jan;42(1 Suppl):S40-3. doi: 10.1161/STROKEAHA.110.606509. Epub 2010 Dec 16.

Comparison of diffusion tensor imaging and voxel-based morphometry to detect white matter damage in Alzheimer's disease

Yoon B, Shim YS, Hong YJ, Koo BB, Kim YD, Lee KO, Yang DW.

J Neurol Sci. 2011 Mar 15;302(1-2):89-95. doi: 10.1016/j.jns.2010.11.012. Epub 2010 Dec 17.

The plasma membrane redox system in Alzheimer's disease

Adlard PA, Bush AI.

Exp Neurol. 2011 Mar;228(1):9-14. doi: 10.1016/j.expneurol.2010.12.009. Epub 2010 Dec 17.

Atorvastatin and Aβ(1-40): not as simple as cholesterol reduction in brain and relevance to Alzheimer disease

Butterfield DA.

Exp Neurol. 2011 Mar;228(1):15-8. doi: 10.1016/j.expneurol.2010.12.014. Epub 2010 Dec 28.

Unraveling the biological mechanisms in Alzheimer's disease--lessons from genomics

Borovecki F, Klepac N, Muck-Seler D, Hajnsek S, Mubrin Z, Pivac N.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Mar 30;35(2):340-7. doi: 10.1016/j.pnpbp.2010.12.019. Epub 2010 Dec 27.

Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action

Barone E, Cenini G, Di Domenico F, Martin S, Sultana R, Mancuso C, Murphy MP, Head E, Butterfield DA.

Pharmacol Res. 2011 Mar;63(3):172-80. doi: 10.1016/j.phrs.2010.12.007. Epub 2010 Dec 27.

Endothelin receptor antagonists: potential in Alzheimer's disease

Palmer J, Love S.

Pharmacol Res. 2011 Jun;63(6):525-31. doi: 10.1016/j.phrs.2010.12.008. Epub 2010 Dec 27.

Amyloid-β and tau--a toxic pas de deux in Alzheimer's disease

Ittner LM, Götz J.

Nat Rev Neurosci. 2011 Feb;12(2):65-72. doi: 10.1038/nrn2967. Epub 2010 Dec 31.

Targeting the hematopoietic system for the treatment of Alzheimer's disease

Lampron A, Gosselin D, Rivest S.

Brain Behav Immun. 2011 Jun;25 Suppl 1:S71-9. doi: 10.1016/j.bbi.2010.12.018. Epub 2010 Dec 30.

The use of mass spectrometry to study amyloid-β peptides

Grasso G.

Mass Spectrom Rev. 2011 May-Jun;30(3):347-65. doi: 10.1002/mas.20281. Epub 2010 Nov 22.

Inclusion body myositis in Alzheimer's disease

Roos PM, Vesterberg O, Nordberg M.

Acta Neurol Scand. 2011 Sep;124(3):215-7. doi: 10.1111/j.1600-0404.2010.01461.x. Epub 2010 Dec 22.

Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study

Kennelly SP, Abdullah L, Paris D, Parish J, Mathura V, Mullan M, Crawford F, Lawlor BA, Kenny RA.

Int J Geriatr Psychiatry. 2011 Oct;26(10):1038-45. doi: 10.1002/gps.2638. Epub 2010 Oct 29.

Assessment of dementia in ethnic minority patients in Europe: a European Alzheimer's Disease Consortium survey

Nielsen TR, Vogel A, Riepe MW, de Mendonça A, Rodriguez G, Nobili F, Gade A, Waldemar G.

Int Psychogeriatr. 2011 Feb;23(1):86-95. doi: 10.1017/S1041610210000955. Epub 2010 Jul 6.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias